OWLT - Owlet seeks FDA medical device approval for its prescription monitor for infants

• Owlet ( NYSE: OWLT ) on Thursday said it was seeking a U.S. FDA medical device approval for its prescription monitor for infants.
• The company filed a so-called 510(k) premarket notification for the device, OWLT said in a statement .
• The monitor is intended to assist with the in-home monitoring of babies under a physician's care, OWLT said.
• The device provides alerts to parents when there are abnormalities in their baby's heart rate or oxygen saturation level.
• Class A shares of OWLT +0.9% to $1.11 in morning trading.

For further details see: